Aqueous liquid composition
The invention provides an aqueous liquid composition comprising a WT1 protein-derived cancer antigen peptide, wherein the peptide is stabilized. The aqueous liquid composition contains a peptide and an excipient, and has a pH of 3-6. The peptide has the amino acid sequence Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu (SEQ ID NO: 1), wherein optionally 1 to 3 amino acids are deleted, substituted and/or added, such that the peptide has a cytotoxic T cell-inducing ability. The excipient is (a) an alpha hydroxyl acid selected from glycolic acid, lactic acid, malic acid, tartaric acid, citric acid and pharmacologically acceptable salts thereof, (b) a dicarboxylic acid selected from malonic acid, succinic acid, glutaric acid, maleic acid and pharmacologically acceptable salts thereof, and/or (c) methionine.
1. An aqueous liquid composition consisting essentially of a peptide and an excipient, and having a pH of 3-6:
wherein the peptide is selected from the group consisting of the amino acid sequences of SEQ ID NOs: 1-7, and
wherein the excipient consists of one or more kinds selected from the group consisting of the following (C), (D) and (E),
(C) one or more kinds of alpha hydroxy acids selected from the group consisting of glycolic acid, lactic acid, malic acid, tartaric acid, citric acid and pharmacologically acceptable salts thereof,
(D) one or more kinds of dicarboxylic acids selected from the group consisting of malonic acid, succinic acid, glutaric acid, maleic acid and pharmacologically acceptable salts thereof, and
(E) methionine.
2. The aqueous liquid composition according to claim 1 , wherein the peptide consists of the amino acid sequence Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu (SEQ ID NO: 1).
3. The aqueous liquid composition according to claim 1 , wherein the excipient consists of both (C) and (E).
4. The aqueous liquid composition according to claim 1 , wherein the excipient consists of both (C) and (E), and (C) is one or more kinds of alpha hydroxy acids selected from the group consisting of glycolic acid, lactic acid, malic acid, tartaric acid and pharmacologically acceptable salts thereof.
5. The aqueous liquid composition according to claim 1 , wherein the excipient consists of both (D) and (E).
6. The aqueous liquid composition according to claim 1 , wherein the excipient consists of both (D) and (E), and (D) is one or more kinds of dicarboxylic acids selected from the group consisting of succinic acid and a pharmacologically acceptable salt thereof.
7. The aqueous liquid composition according to claim 1 , wherein the content per volume of alpha hydroxy acid is 1-100 mM or the content per volume of dicarboxylic acid is 10-100 mM.
8. The aqueous liquid composition according to claim 1 , wherein the content per volume of methionine is 1-300 mM.
9. A method of improving stability of a peptide, consisting of the amino acid sequence shown by Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu (SEQ ID NO: 1), in an aqueous liquid composition by adding an excipient:
wherein
the excipient consists of one or more kinds selected from the group consisting of the following (C), (D) and (E)
(C) one or more kinds of alpha hydroxy acids selected from the group consisting of glycolic acid, lactic acid, malic acid, tartaric acid, citric acid and pharmacologically acceptable salts thereof,
(D) one or more kinds of dicarboxylic acids selected from the group consisting of malonic acid, succinic acid, glutaric acid, maleic acid and pharmacologically acceptable salts thereof, and
(E) methionine, and wherein the aqueous liquid composition after addition of the excipient has a pH of 3-6.
10. The aqueous liquid composition according to claim 2 , wherein the excipient consists of both (C) and (E).
11. The aqueous liquid composition according to claim 2 , wherein the excipient consists of both (C) and (E), and (C) is one or more kinds of alpha hydroxy acids selected from the group consisting of glycolic acid, lactic acid, malic acid, tartaric acid and pharmacologically acceptable salts thereof.
12. The aqueous liquid composition according to claim 11 , wherein the content per volume of alpha hydroxy acid is 1-100 mM.
13. The aqueous liquid composition according to claim 11 , wherein the content per volume of methionine is 1-300 mM.
14. The aqueous liquid composition according to claim 2 , wherein the excipient consists of both (D) and (E).
15. The aqueous liquid composition according to claim 2 , wherein the excipient consists of both (D) and (E), and (D) is one or more kinds of dicarboxylic acids selected from the group consisting of succinic acid and a pharmacologically acceptable salt thereof.
16. The aqueous liquid composition according to claim 15 , wherein the content per volume of dicarboxylic acid is 10-100 mM.
17. The aqueous liquid composition according to claim 15 , wherein the content per volume of methionine is 1-300 mM.